•  
  •  
image-723919-Mission_AD_logo.jpg
image-723919-Mission_AD_logo.jpg
                       
               E2609-G000-302


What follows is a brief summary of the Eisai Pharmaceuticals E2609-G000-302 (MISSION AD2) trial of a beta-secretase inhibitor (elenbecestat) designed to slow down the progression of disease for individuals with mild Alzheimer's disease. 

  • Drug administration -- daily oral    

  • Age range -- 50-85

  • MMSE range -- 24-30

  • Study Duration -- 24 mos.

  • Target population -- Early Alzheimer's (MCI, very mild dementia). Amyloid PET or CSF positive at screening                                                                        

  • Mechanism of action --  blocks formation of active beta amyloid protein (BACE inhibition)

  • Randomization split -- 1:1,  active : placebo

  • Type(s) of imaging -- brain MRI, CT, amyloid PET, Tau PET


For more details on this specific trial, visit:


ClinicalTrials.gov
                                                                         
             A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060